scholarly article | Q13442814 |
P50 | author | Frederick R. Appelbaum | Q75025725 |
P2093 | author name string | Anderson J | |
P921 | main subject | myelodysplastic syndrome | Q954625 |
P304 | page(s) | S25-9 | |
P577 | publication date | 1998-09-01 | |
P1433 | published in | Leukemia | Q6534498 |
P1476 | title | Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score | |
P478 | volume | 12 Suppl 1 |
Q36402045 | A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. |
Q50079881 | Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation |
Q34996203 | Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis |
Q36768610 | Azacitidine in the management of patients with myelodysplastic syndromes |
Q36608689 | CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse |
Q39214508 | Cancer Care at Times of Crisis and War: The Syrian Example |
Q46654906 | Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome |
Q43166941 | Components of the revised International Prognostic Scoring System and outcome after hematopoietic cell transplantation for myelodysplastic syndrome |
Q50778042 | Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan. |
Q35925067 | Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematol |
Q34272525 | Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a [...] |
Q35739130 | Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY |
Q33389333 | Management of myelodysplastic syndromes in the geriatric patient |
Q37448906 | Managing myelodysplastic symptoms in elderly patients. |
Q36683757 | Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome |
Q39276603 | Monosomal karyotype in myeloid neoplasias: a literature review |
Q36110604 | Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C |
Q38965973 | Myelodysplastic Syndromes: Updates and Nuances |
Q43082895 | Myelodysplastic syndrome: An update on diagnosis and therapy |
Q37244697 | Myelodysplastic syndrome: an update on diagnosis and therapy |
Q35291851 | Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). |
Q35193735 | Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. |
Q36920394 | Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and M |
Q37738511 | Stem cell transplantation for myelodysplastic syndromes: the lure of a cure. |
Q41902244 | Stem cells in hemato-oncology |
Q34996351 | The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002). |
Q34418429 | The role of azacitidine in the management of myelodysplastic syndromes (MDS). |
Q30240238 | Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens |
Q35838113 | Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings |
Q45756342 | Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. |
Search more.